Labcorp Appoints Victor Bulto to Board of Directors

Rhea-AI Summary

Labcorp (NYSE: LH) announced the appointment of Victor Bulto to its Board of Directors, effective December 1, 2025. Bulto currently leads Novartis' U.S. business, a $20+ billion operation, and brings 25 years of global healthcare leadership across oncology, immunology, neuroscience, and cardiovascular-renal-metabolic areas.

Labcorp highlighted his experience in transformation, technology and automation, and commercial strategy as supportive of its long-term growth priorities in precision medicine, patient access to novel therapies, and innovation through science and technology.

Bulto, President, U.S. of Novartis, brings global healthcare leadership and growth track record to support Labcorp's long-term strategy

BURLINGTON, N.C., Nov. 24, 2025 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the appointment of Victor Bulto, a seasoned pharmaceutical executive and member of Novartis' executive leadership team, to its Board of Directors, effective December 1, 2025.

Bulto is an accomplished global executive with 25 years of experience in healthcare, and a proven track record of leading large, complex organizations across the U.S. and Europe. He currently oversees Novartis' U.S. business—a $20+ billion operation—with responsibility across four key therapeutic areas: oncology, immunology, neuroscience, and cardiovascular-renal-metabolic. Throughout his career at Novartis, Bulto has shaped bold strategies and delivered commercial excellence, enabling businesses to stay ahead amid intensifying regulatory and market pressures. He brings deep expertise in transformation, harnessing technology and automation to simplify processes, drive efficiency, and build future-ready operating models. By anticipating opportunities and building toward them, he drives progress at the evolving intersection of healthcare innovation and consumer expectations, creating new pathways for patient-centered care.

"Victor's appointment to our Board underscores Labcorp's focus on long-term growth through innovation and global healthcare leadership," said Adam Schechter, Chairman and Chief Executive Officer of Labcorp. "His experience leading one of the largest pharmaceutical businesses in the U.S., combined with his expertise across key therapeutic areas, will be invaluable as we advance our strategic priorities and focus on innovating through science and technology to deliver greater value for our customers and shareholders."

"I deeply believe in Labcorp's mission and am honored to join the Board at a time of industry growth and medical advancement, particularly in the field of precision medicine," said Bulto. "Labcorp's scale and infrastructure, combined with its commitment to meaningful patient impact, create a unique opportunity to accelerate access to novel therapies and shape the future of healthcare."

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/labcorp-appoints-victor-bulto-to-board-of-directors-302623576.html

SOURCE Labcorp Holdings Inc

FAQ

Who is Victor Bulto and when does he join Labcorp's board (LH)?

Victor Bulto is president of Novartis U.S.; he joins Labcorp's board effective December 1, 2025.

What experience does Victor Bulto bring to Labcorp (NYSE: LH)?

He has 25 years in healthcare and oversees Novartis' U.S. business, a $20+ billion operation across multiple therapeutic areas.

How might Victor Bulto's appointment affect Labcorp's strategy (LH)?

Labcorp expects his expertise in transformation, technology, and commercial strategy to support long-term growth and precision medicine initiatives.

What areas of expertise does Victor Bulto have relevant to Labcorp (LH)?

Bulto has experience in oncology, immunology, neuroscience, cardiovascular-renal-metabolic, plus technology-driven operational transformation.

Who commented on Victor Bulto's appointment to Labcorp's board (LH)?

Adam Schechter, Labcorp chairman and CEO, said the appointment underscores the company's focus on long-term growth through innovation and global healthcare leadership.

Will Victor Bulto's board role at Labcorp (LH) change his position at Novartis?

The announcement states he continues to oversee Novartis' U.S. business and does not indicate any change to his current role.